Navigation Links
New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
Date:10/17/2008

MONTREAL, Oct. 17 /PRNewswire-FirstCall/ -- Today, at the Canadian Diabetes Association Congress, physicians will get a first-time look at more detailed results from a phase 3b clinical study (LEAD(TM) 6) comparing the investigational new drug liraglutide to exenatide. The study showed that liraglutide, a human GLP-1 analog administered once daily was significantly more effective at improving blood glucose control (as measured by HbA1c) than exenatide, a GLP-1 mimetic administered twice daily.

"In this study, reduction in blood glucose was greater with liraglutide than with exenatide," said Lawrence Blonde, MD, Director of the Ochsner Diabetes Clinical Research Unit in the Department of Endocrinology, Diabetes, and Metabolism at the Oxford Center in New Orleans. "Patients treated with once-daily liraglutide achieved better blood glucose control and also had less minor hypoglycemia than those treated with exenatide."

Fasting plasma glucose was also reduced significantly more with liraglutide compared to exenatide. Furthermore, liraglutide was also associated with higher HOMA-B values, an assessment of beta-cell function.

The 26-week study included 464 people with type 2 diabetes who were randomized to treatment with either liraglutide 1.8 mg once daily or exenatide 10 micrograms twice daily, both as an add-on to their existing treatment consisting of metformin and/or a sulphonylurea.

The overall rate of hypoglycemia in the study was low. Liraglutide patients experienced significantly less minor hypoglycemia compared to those on exenatide.

Nausea was the most common side effect for both treatments and was reported at a level of 25.5% in the liraglutide group and 28% in exenatide group (percent of all study participants reporting nausea at least once). However, in the liraglutide group, the percentage of patients reporting nausea in each week fell to 8% after 5 weeks, 4% after 10 weeks and 3% after 26 weeks. In the exenatide gr
'/>"/>

SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013  Cleveland BioLabs, Inc. (NASDAQ: CBLI) ... the Second Annual Marcum LLP Microcap Conference, May 30, in ... Neil Lyons , CPA, Chief Financial Officer ... programs on May 30 at 1:30 p.m. Eastern Time.  A ... available on the Investors page of the Cleveland BioLabs website ...
(Date:5/22/2013)... Express Diagnostics Int’l, Inc. (EDI) ... are pleased to announce a sponsorship agreement with Erebus ... Zealand distributor of DrugCheck® onsite testing devices, manufactured by ... the Austin 400 May 17-19 in Austin, Texas. , ... involves each car of the Erebus Motorsport team displaying ...
(Date:5/22/2013)... Miami, FL (PRWEB) May 22, 2013 A ... effects of probiotics on athletes to find that those who ... percent longer. The results from the study showed that in ... Probiotic Action, known for their adult acne treatment ... acne, and how it may help their skin condition. ...
(Date:5/21/2013)... , May 22, 2013 First ... formulation of glycopyrronium bromide designed using Prosonix, particle engineering ... developing a portfolio of inhaled Respiratory Medicines by ... with PSX1002 that will assess its effect on lung ... in patients with moderate to severe chronic obstructive pulmonary ...
Breaking Biology Technology:Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference 2Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team 2Adult Acne Treatment, Probiotic Action Shares Insight on New Findings Between Probiotics and Heat Tolerance, and What It Means for Acne Sufferers 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4
... in Second Pivotal Clinical Trial , WASHINGTON, Nov. ... today announced positive results from BLISS-76, the second of ... for treating systemic lupus. A full presentation of ... Annual Scientific meeting of the American College of Rheumatology. ...
... powder from her ring into wine glasses carelessly left unattended. ... holding a cabochon or faceted gemstone that can be broken ... so large it is rather odd nobody seems to notice ... the "smart capsule" devised in Younan Xia,s laboratory at ...
... DIEGO and INDIANAPOLIS, Oct. 30, 2009 Amylin Pharmaceuticals, Inc., ... LLY ) today announced that the U.S. Food and ... (exenatide) injection. BYETTA is now approved for use as a ... glycemic control in adults with type 2 diabetes. Previously, it ...
Cached Biology Technology:Promise of a New Lupus Treatment Is a Groundbreaking Achievement 2Promise of a New Lupus Treatment Is a Groundbreaking Achievement 3An exquisite container 2An exquisite container 3An exquisite container 4An exquisite container 5BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 2BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 3BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 4BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 5BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 6BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 7
(Date:5/21/2013)... University researchers have developed a new method for ... holes in the cell surface. The technique could ... related biological fields. , Bulk electroporation a ... reversible nanopores in the cell membrane that are ... is an increasingly popular method of cell transfection. ...
(Date:5/21/2013)... new University of Michigan Water Center today awarded ... Great Lakes restoration and protection efforts. , The ... diverse projects, including efforts to track the remediation ... techniques to control non-native weedy plant invasions; study ... fish responses to restoration activities. , The grants ...
(Date:5/21/2013)... Researchers at the University of Illinois at Chicago College of ... and stores fat -- its main energy source -- and ... disease, under a new $2 million, 4-year grant from the ... heart changes how it uses fuel for energy. These changes ... disease and are different in men and women, says E. ...
Breaking Biology News(10 mins):Single-cell transfection tool enables added control for biological studies 2U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4Do men's and women's hearts burn fuel differently? 2
... A&M Institute of Renewable Natural Resources have discovered fresh remains ... Texas, according to a research associate with the institute. ... individual of false spike "Quadrula mitchelli" with tissue still in ... alive in the San Saba River in ...
... at the Gladstone Institutes have gained new insight into the ... can prevent the normal development of stem cells in the ... cancer. "The news, being announced in a paper published ... the understanding of the role of stem cells in embryonic ...
... new research that could have implications for improving fertilization ... between individual sperm and eggs in red abalone, an ... models of these interactions. They are the first scientists ... natural habitat of the abalone in the laboratory, the ...
Cached Biology News:Researchers discover freshwater mussel species thought to be extinct 2Researchers discover freshwater mussel species thought to be extinct 3Researchers discover freshwater mussel species thought to be extinct 4Gladstone scientists offer new insight into the regulation of stem cells and cancer cells 2Gladstone scientists offer new insight into the regulation of stem cells and cancer cells 3UCLA life scientists' study of abalone yields new insights into sexual reproduction 2UCLA life scientists' study of abalone yields new insights into sexual reproduction 3UCLA life scientists' study of abalone yields new insights into sexual reproduction 4
Request Info...
ROCK-1 (cleaved) Monoclonal Ab 100 ug purified mouse monoclonal antibody. Clone# 12M03. Reacts with human. Tested in Western blot analysis....
Anti-Cullin-1 Host: rabbit polyclonal Species Reactivity: human, mouse Applications: IHC(P), WB, IP Storage: 4C...
Request Info...
Biology Products: